Torrent Pharmaceuticals Limited has successfully completed a United States Food and Drug Administration (USFDA) inspection at its Dahej manufacturing facility with zero observations, marking a significant regulatory milestone for the pharmaceutical company.

Inspection Details

The USFDA conducted a comprehensive inspection of the Dahej manufacturing facility over a five-day period. The inspection parameters and outcomes are detailed below:

Regulatory Compliance Achievement

The completion of the USFDA inspection with zero observations represents a clean regulatory outcome for Torrent Pharmaceuticals. Zero observations indicate that the inspection team found no deficiencies or areas of concern during their comprehensive review of the facility's manufacturing processes, quality systems, and compliance protocols.

This outcome demonstrates the company's adherence to stringent international manufacturing standards and regulatory requirements set by the USFDA for pharmaceutical facilities.

Stock Exchange Notification

Torrent Pharmaceuticals has formally notified both major Indian stock exchanges about this development in compliance with regulatory disclosure requirements:

• BSE Limited: Notification sent under Scrip Code 500420
• National Stock Exchange: Notification sent under Symbol TORNTPHARM
• Regulatory Framework: Disclosed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The notification was signed by Chintan M. Trivedi, Company Secretary, and submitted on January 23, 2026.

Manufacturing Facility Significance

The Dahej facility represents an important manufacturing asset for Torrent Pharmaceuticals in its pharmaceutical operations. The successful completion of this USFDA inspection without any observations strengthens the facility's regulatory standing and validates the company's manufacturing capabilities for potential US market operations.

This regulatory clearance enhances the company's compliance track record and supports its pharmaceutical manufacturing operations under international quality standards.

Torrent Pharmaceuticals announced the completion of its landmark acquisition of JB Chemicals & Pharmaceuticals on January 21, 2026, marking a significant consolidation in India's pharmaceutical sector. The transaction involved purchasing 7,44,81,519 shares representing 46.39% of JB Pharma's fully diluted equity from Tau Investment Holdings Pte. Ltd., a KKR entity, under agreements signed in June and July 2025.

Transaction Details

The acquisition forms part of a comprehensive transaction valuing JB Pharma at ₹25,689 crore on a fully diluted basis. The deal structure encompasses multiple components designed to maximize Torrent's control over the target company.

With the acquisition completed and an additional 1,317 shares acquired through the open offer, Torrent has formally assumed controlling promoter status at JB Pharma. JB Pharma's board convened the same day to acknowledge the change in control and reclassify Tau as a public shareholder under SEBI regulations.

Leadership Transformation

The change in control has prompted extensive restructuring of JB Pharma's governance framework. Three non-executive, non-independent directors resigned immediately following the board meeting, citing the need to facilitate reconstitution under new ownership.

The management changes extend to senior leadership positions. Nikhil Chopra, JB Pharma's Whole-time Director and Chief Executive Officer, tendered his resignation as Whole-time Director effective immediately. However, he will continue serving as CEO until March 31, 2026, before exiting the company entirely to pursue other professional opportunities.

New Board Appointments

Torrent Pharma has nominated a slate of experienced executives to JB Pharma's reconstituted board. Aman Mehta, Managing Director of Torrent Pharma, has been appointed Managing Director of JB Pharma for a three-year term. Mehta brings extensive operational experience from his decade-long tenure within the Torrent Group, having played key roles in previous acquisitions including Unichem and Curatio.

Strategic Implications

The acquisition strengthens Torrent's position in branded generics and chronic therapies, leveraging JB Pharma's established franchises in gastrointestinal, hypertension, and pediatric categories. With operational control secured and management realigned, the transaction positions Torrent to accelerate portfolio expansion, supply-chain integration, and margin improvements within its India-focused growth strategy.

JB Pharma's board committees have been reconstituted effective January 21, 2026, and the company will seek shareholder approval for the new appointments through a postal ballot process. The successful completion of this acquisition represents one of the largest pharmaceutical sector consolidations in recent years, combining Torrent's operational expertise with JB Pharma's therapeutic strengths.